IDOSE TR

Growth

travoprost intracameral

Glaukos
NDAINTRACAMERALIMPLANT
Approved
Dec 2023
Lifecycle
Growth
Competitive Pressure
8/100
Clinical Trials
3

Mechanism of Action

acid, a prostaglandin analog is a selective FP prostanoid receptor agonist, which is believed to reduce IOP by increasing uveoscleral outflow. The exact mechanism of action is unknown at this time.

Pharmacologic Class:

Prostaglandin Analog

Indications (4)

intraocular pressure (IOP) in patients with open-angle glaucoma (OAG)ocular hypertension (OHT)ocular hypertension (OHT) ()hypertension

Clinical Trials (3)

NCT07228221Phase 4Recruiting

Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma

Started Jan 2026
NCT07400926N/ARecruiting

Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg

Started Dec 2025
NCT07075718Phase 2/3Recruiting

Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Started Jun 2025

Loss of Exclusivity

LOE Date
Feb 14, 2031
60 months away
Patent Expiry
Feb 14, 2031
Exclusivity Expiry
Dec 13, 2026

Patent Records (4)

Patent #ExpiryTypeUse Code
12201557
Jun 18, 2030
SubstanceProduct
U-4129
10206813
Oct 17, 2030
Product
—
11426306
Oct 17, 2030
Product
—
12201555
Feb 14, 2031
SubstanceProduct
—
Company
Glaukos
Glaukos
ALISO VIEJO, CA
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers